Subscribe To
NVO / The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
NVO News
By The Motley Fool
November 3, 2023
Why Novo Nordisk Stock Flopped on Friday
An analyst's price target bump was overshadowed by an insider's stock sale. Both were relatively small-scale events. more_horizontal
By Proactive Investors
November 3, 2023
Novo Nordisk to release clinical update on star drug Wegovy
Novo Nordisk (NYSE:NVO) remains firmly in favour with analysts at Barclays ahead of the latest trial data for diabetes drug Wegovy that is due next we more_horizontal
By Yahoo Finance
November 2, 2023
Weight loss drug Wegovy sales fuel Novo Nordisk stock performance
Novo Nordisk (NVO) stock rose after the pharmaceutical company reported strong third-quarter sales growth, fueled by its popular weight-loss drug, Weg more_horizontal
By Reuters
November 2, 2023
Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month
The majority of U.S. patients with health insurance coverage taking Novo Nordisk's powerful weight-loss drug Wegovy are paying less than $25 per month more_horizontal
By Bloomberg Markets and Finance
November 2, 2023
US Wegovy Supply to Expand ‘Gradually': Novo Nordisk CEO
Novo Nordisk CEO Lars Fruergaard Jorgensen says starter doses of the company's weight loss medications will “be lowered somewhat” through the end more_horizontal
By CNBC
November 2, 2023
Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
Novo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months more_horizontal
By Reuters
November 2, 2023
Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic
Novo Nordisk is ramping up its in-house manufacturing capacity to fill injection pens for its diabetes drug Ozempic and for the European version of it more_horizontal
By Reuters
November 2, 2023
Novo Nordisk: obesity drugs priority over century-old focus on insulin
Novo Nordisk said on Thursday treating obesity with its weight-loss drug Wegovy as a precursor to type 2 diabetes was a priority for the company, cont more_horizontal